| 1. Executive Summary |
| 2. Global Oncology Market Introduction |
| 2.1. Global Oncology Market - Taxonomy |
| 2.2. Global Oncology Market -Definitions |
| 2.2.1. By Drug Class |
| 2.2.2. By Disease Indications |
| 2.2.3. By Treatment Options |
| 2.2.4. By Distribution Channel |
| 2.2.5. By Region |
| 3. Global Oncology Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Oncology Market Dynamic Factors - Impact Analysis |
| 3.6. Impact of COVID 19 on The Market |
| 3.7. Three Forecast Scenarios - Pessimistic, Conservative, and Opportunistic |
| 3.8. Mapping Market Players Activities |
| 3.9. Recent Key Developments |
| 3.10. Financial Status of the Market Players |
| 3.11. Recent Acquisitions, Collaborations, and Mergers |
| 4.Global Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Oncology Market Forecast, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.1. Antimetabolites |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. MAbs |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. XPO1 Inhibitor |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Mitotic Inhibitors |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Multikinase Inhibitors |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Antineoplastics |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6.Global Oncology Market Forecast, By Disease Indications, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.1. Lung cancer |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Breast cancer |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Prostate cancer |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Cervical cancer |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Colorectal cancer |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Acute Myeloid Leukemia |
| 6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Others |
| 6.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 7. Market Opportunity Analysis Global Oncology Market Forecast, By Treatment Options, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.1. Surgery |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Chemotherapy |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Immunotherapy |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Targeted Therapy |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Bone marrow transplant |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Bone marrow transplant |
| 7.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.6.3. Market Opportunity Analysis |
| 7.7. Hormone therapy |
| 7.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.7.3. Market Opportunity Analysis |
| 7.8. Cryoablation |
| 7.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.8.3. Market Opportunity Analysis |
| 7.9. Cryoablation |
| 7.9.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.9.3. Market Opportunity Analysis |
| 7.10. Radiofrequency ablation |
| 7.10.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.10.3. Market Opportunity Analysis |
| 7.11. Radiation Therapy |
| 7.11.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.11.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.11.1.3. Market Opportunity Analysis |
| 7.12. Others |
| 7.12.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.12.3. Market Opportunity Analysis |
| 8. Market Opportunity Analysis Global Oncology Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 8.1. Hospital Pharmacy |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Retail Pharmacy |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Online Pharmacy |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9. Global Oncology Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia-Pacific |
| 9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Latin America |
| 9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Middle East and Africa |
| 9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 9.6. Global Oncology Market - Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel, and Region, 2023 - 2029 |
| 10. North America Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 10.1. By Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.1.1. Antimetabolites |
| 10.1.2. Antineoplastics |
| 10.1.3. XPO1 Inhibitor |
| 10.1.4. Mitotic Inhibitors |
| 10.1.5. Biomarker testing |
| 10.1.6. Multikinase Inhibitors |
| 10.2. By Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Lung cancer |
| 10.2.2. Breast cancer |
| 10.2.3. Prostate cancer |
| 10.2.4. Cervical cancer |
| 10.2.5. Colorectal cancer |
| 10.2.6. Acute Myeloid Leukemia |
| 10.2.7. Others |
| 10.3. By Treatment Options Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Surgery |
| 10.3.2. Chemotherapy |
| 10.3.3. Radiation therapy |
| 10.3.4. Bone marrow transplant |
| 10.3.5. Immunotherapy |
| 10.3.6. Hormone therapy |
| 10.3.7. Targeted drug therapy |
| 10.3.8. Cryoablation |
| 10.3.9. Radiofrequency ablation |
| 10.4. By Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Hospital Pharmacy |
| 10.4.2. Retail Pharmacy |
| 10.4.3. Online Pharmacy |
| 10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 10.5.1. U.S. |
| 10.5.2. Canada |
| 10.6. North America Oncology Market - Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel and Country, 2023 - 2029 |
| 10.7. North America Oncology Market Dynamics - Trends |
| 11. Europe Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 11.1. By Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.1.1. Antimetabolites |
| 11.1.2. Antineoplastics |
| 11.1.3. XPO1 Inhibitor |
| 11.1.4. Mitotic Inhibitors |
| 11.1.5. Biomarker testing |
| 11.1.6. Multikinase Inhibitors |
| 11.2. By Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Lung cancer |
| 11.2.2. Breast cancer |
| 11.2.3. Prostate cancer |
| 11.2.4. Cervical cancer |
| 11.2.5. Colorectal cancer |
| 11.2.6. Acute Myeloid Leukemia |
| 11.2.7. Others |
| 11.3. By Treatment Options Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Surgery |
| 11.3.2. Chemotherapy |
| 11.3.3. Radiation therapy |
| 11.3.4. Bone marrow transplant |
| 11.3.5. Immunotherapy |
| 11.3.6. Hormone therapy |
| 11.3.7. Targeted drug therapy |
| 11.3.8. Cryoablation |
| 11.3.9. Radiofrequency ablation |
| 11.4. By Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Hospital Pharmacy |
| 11.4.2. Retail Pharmacy |
| 11.4.3. Online Pharmacy |
| 11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 11.5.1. Germany |
| 11.5.2. UK |
| 11.5.3. France |
| 11.5.4. Italy |
| 11.5.5. Spain |
| 11.5.6. Rest of Europe |
| 11.6. Europe Oncology Market - Opportunity Analysis Index, By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel and Country, 2023 - 2029 |
| 11.7. Europe Oncology Market Dynamics - Trends |
| 12. Asia-Pacific Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 12.1. By Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.1.1. Antimetabolites |
| 12.1.2. Antineoplastics |
| 12.1.3. XPO1 Inhibitor |
| 12.1.4. Mitotic Inhibitors |
| 12.1.5. Biomarker testing |
| 12.1.6. Multikinase Inhibitors |
| 12.2. By Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Lung cancer |
| 12.2.2. Breast cancer |
| 12.2.3. Prostate cancer |
| 12.2.4. Cervical cancer |
| 12.2.5. Colorectal cancer |
| 12.2.6. Acute Myeloid Leukemia |
| 12.2.7. Others |
| 12.3. By Treatment Options Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Surgery |
| 12.3.2. Chemotherapy |
| 12.3.3. Radiation therapy |
| 12.3.4. Bone marrow transplant |
| 12.3.5. Immunotherapy |
| 12.3.6. Hormone therapy |
| 12.3.7. Targeted drug therapy |
| 12.3.8. Cryoablation |
| 12.3.9. Radiofrequency ablation |
| 12.4. By Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Hospital Pharmacy |
| 12.4.2. Retail Pharmacy |
| 12.4.3. Online Pharmacy |
| 12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 12.5.1. Japan |
| 12.5.2. China |
| 12.5.3. India |
| 12.5.4. ASEAN |
| 12.5.5. Rest of Asia-Pacific |
| 12.6. Asia-Pacific Oncology Market - Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel and Country, 2023 - 2029 |
| 12.7. Asia-Pacific Oncology Market Dynamics - Trends |
| 13. Latin America Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 13.1. By Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 13.1.1. Antimetabolites |
| 13.1.2. Antineoplastics |
| 13.1.3. XPO1 Inhibitor |
| 13.1.4. Mitotic Inhibitors |
| 13.1.5. Biomarker testing |
| 13.1.6. Multikinase Inhibitors |
| 13.2. By Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Lung cancer |
| 13.2.2. Breast cancer |
| 13.2.3. Prostate cancer |
| 13.2.4. Cervical cancer |
| 13.2.5. Colorectal cancer |
| 13.2.6. Acute Myeloid Leukemia |
| 13.2.7. Others |
| 13.3. By Treatment Options Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Surgery |
| 13.3.2. Chemotherapy |
| 13.3.3. Radiation therapy |
| 13.3.4. Bone marrow transplant |
| 13.3.5. Immunotherapy |
| 13.3.6. Hormone therapy |
| 13.3.7. Targeted drug therapy |
| 13.3.8. Cryoablation |
| 13.3.9. Radiofrequency ablation |
| 13.4. By Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Hospital Pharmacy |
| 13.4.2. Retail Pharmacy |
| 13.4.3. Online Pharmacy |
| 13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 13.5.1. Brazil |
| 13.5.2. Argentina |
| 13.5.3. Rest of Latin America |
| 13.6. Latin America Oncology Market - Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel and Country, 2023 - 2029 |
| 13.7. Latin America Oncology Market Dynamics - Trends |
| 14. Middle East and Africa Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 14.1. By Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 14.1.1. Antimetabolites |
| 14.1.2. Antineoplastics |
| 14.1.3. XPO1 Inhibitor |
| 14.1.4. Mitotic Inhibitors |
| 14.1.5. Biomarker testing |
| 14.1.6. Multikinase Inhibitors |
| 14.2. By Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 14.2.1. Lung cancer |
| 14.2.2. Breast cancer |
| 14.2.3. Prostate cancer |
| 14.2.4. Cervical cancer |
| 14.2.5. Colorectal cancer |
| 14.2.6. Acute Myeloid Leukemia |
| 14.2.7. Others |
| 14.3. By Treatment Options Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 14.3.1. Surgery |
| 14.3.2. Chemotherapy |
| 14.3.3. Radiation therapy |
| 14.3.4. Bone marrow transplant |
| 14.3.5. Immunotherapy |
| 14.3.6. Hormone therapy |
| 14.3.7. Targeted drug therapy |
| 14.3.8. Cryoablation |
| 14.3.9. Radiofrequency ablation |
| 14.4. By Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 14.4.1. Hospital Pharmacy |
| 14.4.2. Retail Pharmacy |
| 14.4.3. Online Pharmacy |
| 14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 14.5.1. Saudi Arabia |
| 14.5.2. GCC Countries |
| 14.5.3. South Africa |
| 14.5.4. Rest of MEA |
| 14.6. MEA Oncology Market - Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel and Country, 2023 - 2029 |
| 14.7. MEA Oncology Market Dynamics - Trends |
| 15. Competition Landscape |
| 15.1. Strategic Dashboard of Top Market Players |
| 15.2. Company Profiles (Introduction, Financial Analysis, By Drug Class Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 15.2.1. ABBVIE INC.AMGEN, INC. |
| 15.2.2. ASTELLAS PHARMA INC. |
| 15.2.3. ASTRAZENECA PLC |
| 15.2.4. BRISTOL-MYERS SQUIBB COMPANY |
| 15.2.5. F. HOFFMANN-LA ROCHE AG |
| 15.2.6. JOHNSON & JOHNSON |
| 15.2.7. MERCK & CO., INC. |
| 15.2.8. NOVARTIS INTERNATIONAL AG |
| 15.2.9. PFIZER, INC. |
| 15.2.10. Celgene Corporation (U.S.) |
| 16. Research Methodology |
| 17. Key Assumptions and Acronyms |
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
2021 is the base year and 2028 is the forecast year.
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
The oncology market key players are: ABBVIE INC., AMGEN, INC., ASTELLAS PHARMA INC., ASTRAZENECA PLC, BRISTOL-MYERS SQUIBB COMPANY, JOHNSON & JOHNSON, MERCK & CO., INC., NOVARTIS INTERNATIONAL AG, PFIZER, INC., Celgene Corporation (U.S.), HOFFMANN-LA ROCHE AG
- ABBVIE INC.
- AMGEN, INC.
- ASTELLAS PHARMA INC.
- ASTRAZENECA PLC
- BRISTOL-MYERS SQUIBB COMPANY
- JOHNSON & JOHNSON
- MERCK & CO., INC.
- NOVARTIS INTERNATIONAL AG
- PFIZER, INC.
- Celgene Corporation (U.S.)
- HOFFMANN-LA ROCHE AG